Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome (NCT04327934), a randomized early/phase 1 study. The primary outcome is Baroreflex Response to LBNP.

2. Clinical Question

3. Trial Design

The registry record describes a randomized, unmasked, parallel study classified as early phase 1. Enrollment is listed as 28. The study status is terminated. The record gives a start date of 2017-12-01 and a primary completion date of 2022-06-30. It names Yale University as sponsor.

The arm descriptions are Healthy Control, described as healthy control participants, and AE-PCOS, described as participants with AE-PCOS. The listed drug interventions are GnRH antagonist and GnRH antagonist + MethylTESTOSTERone 5 MG. Although allocation is recorded as randomized, the record does not clarify the relationship between the intervention entries and the two arm descriptions. It also does not describe the randomization procedure, allocation ratio, or which participants received which intervention.

The primary outcome is assessed at baseline, at 7 days of GnRH, and at 16 days of GnRH plus 5 days of testosterone. These are multiple assessment conditions, rather than a single time point. The record does not specify a single primary comparison across groups or times. It lists aldosterone and renal responses as secondary outcomes, with 10 outcome measures and 9 analyses recorded.

These design details establish the broad structure of the study but do not establish what analysis was planned or performed. The reason for termination, recruitment progress, protocol deviations, and any changes to the design are not reported in the registry record. Nor does the record state whether all participants completed every scheduled assessment.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Baseline characteristics are presented for people that completed the study- which is defined as those that were allocated, began and completed the study.

6. Primary Endpoint

The registry lists the primary outcome as Baroreflex Response to LBNP, measured over Baseline, assessed at 7 days of GnRH, assessed at 16 days GnRH+ 5 days of Testosterone.

The primary endpoint is titled Baroreflex Response to LBNP. It is described as forearm blood flow, assessed by ultrasound, divided by mean arterial pressure, evaluated as a linear function of lower body negative pressure. The unit is Arbitrary Units/Beat/mmHg. The registry record specifies a mean as the summary measure and standard deviation as the dispersion measure.

In general, lower body negative pressure causes blood pooling in the lower body. The endpoint description treats the relationship between this pressure challenge and the forearm blood-flow measure as an indicator of autonomic control of blood pressure. It is intended to reflect the sensitivity of vessel-diameter changes in response to blood pooling. This is a physiological measure, not a direct count of clinical events or a patient-reported symptom.

Because the endpoint is described as a linear function, its interpretation depends on the fitted relationship between the response and the pressure challenge. In general, a slope describes how an outcome changes as its explanatory variable changes. The record does not report numerical slopes, group means, standard deviations, confidence intervals, or a statistical test for this endpoint. It also does not give enough information to identify which slope contrast was designated as the primary comparison.

The scheduled assessments are baseline, 7 days of GnRH, and 16 days of GnRH plus 5 days of testosterone. The registry record does not report endpoint values at these assessments. Therefore, the endpoint definition explains what was intended to be measured, but not what the measurements showed.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does a mean with a standard deviation describe?

The primary outcome is specified as a mean of a continuous measure, with standard deviation as its dispersion statistic. In general, the mean describes the arithmetic average of measured values. The standard deviation describes the spread of individual observations around that average. These answer different questions: the mean locates the center of the observed measurements, while the standard deviation characterizes their variability.

A standard deviation is not the same as the uncertainty in a group mean or a treatment contrast. In general, uncertainty about an estimated mean or contrast is expressed by a standard error or confidence interval, which also depends on the amount of information available and the analysis. The registry record does not report these quantities for the primary outcome, so neither the variability of the measurements nor the precision of a comparison can be assessed from a numerical result.

What is a linear-function endpoint?

The endpoint description relates forearm blood flow divided by mean arterial pressure to lower body negative pressure as a linear function. In general, a linear model represents the average relationship between an outcome and an explanatory variable using a straight-line form. A slope represents the estimated change in the outcome associated with a change in the explanatory variable. The exact interpretation depends on the model specification, units, and coding.

Here, the registry record explains the physiological purpose of the measure but does not report the model equation, estimated slope, uncertainty, or how slopes would be compared across groups or assessment conditions. It is therefore possible to explain the intended type of measurement, but not to interpret a fitted effect or infer its direction.

Why does the study structure matter?

Random allocation is a design feature intended, in general, to reduce systematic differences between groups at assignment. The record labels the study randomized, but does not report the randomization method, allocation ratio, concealment, or the mapping of drug interventions to the described groups. Those omissions limit what can be said about the specific comparison. The study is also labeled unmasked, meaning masking is recorded as none; details about who knew allocation and when are not reported.

A parallel model generally means groups are followed in separate arms rather than participants crossing through each assigned treatment condition. The record labels the model parallel and lists the Healthy Control and AE-PCOS descriptions. It does not provide enough detail to establish whether those descriptions correspond directly to randomized intervention arms. Thus, the broad design label should not be mistaken for a complete account of the treatment comparison.

Why can over-dispersion matter?

In general, over-dispersion occurs when observed variability is greater than a statistical model assumes. If a model understates variability, uncertainty intervals may be too narrow and tests may overstate evidence against a null hypothesis. Appropriate methods depend on the outcome distribution and design. The primary endpoint is described as continuous and summarized using a mean and standard deviation; no over-dispersion assessment or modeling strategy is reported in the registry record. This general issue does not establish that over-dispersion occurred in this study.

What can be inferred from the analysis counts?

The record lists 10 outcome measures and 9 analyses. These counts do not identify the statistical methods, the number of comparisons for any one outcome, or which analysis was primary. They also do not show whether analyses were prespecified, adjusted, or exploratory. The registry record does not report a statistical analysis plan, model details, covariate adjustments, handling of repeated measurements, or a method for calculating uncertainty.

The record states planning assumptions for sample-size illustrations: two-sided significance level 0.05, equal allocation between two arms, and a normal approximation, with the detectable effect defined as a fraction of the observed effect. These are described as planning illustrations, not the trial's own design. The observed effect is not reported in the registry record, and no numerical planning results are reported in the registry record for this explanation. Such illustrations, in general, are not observed power and do not substitute for the actual analysis or its uncertainty.

The registry record does not report interim analyses, stopping rules, missing-data methods, or analysis populations. None should be inferred from the early phase 1 label or terminated status. Without the analysis details and numerical results, statistical concepts can clarify what the design and endpoint mean, but cannot supply a study finding.

10. Multiplicity, Missing Data and Analysis Populations

The record lists 10 outcome measures and 9 analyses, but does not report how many hypotheses were tested for each outcome, which results were considered primary, or whether any multiplicity adjustment was planned or used. When many outcomes, groups, or time points are analyzed, the chance of at least one apparently unusual result can increase. In general, multiplicity procedures address that issue by adjusting interpretation or testing thresholds. Whether such procedures were appropriate or applied in this study is not reported in the registry record.

The primary endpoint has three stated assessment conditions: baseline, 7 days of GnRH, and 16 days of GnRH plus 5 days of testosterone. The record does not identify the primary contrast among these conditions, or explain how repeated measurements on the same participant were handled. It also does not report whether the main question concerned between-group differences, within-participant change, or an interaction between group and time.

Missing-data information is not reported in the registry record. There is no account of participants with incomplete assessments, reasons for missing measurements, or methods used to address missingness. The number enrolled does not establish the number included in any outcome analysis.

Analysis populations are also not reported. The record does not say whether analyses followed randomized assignment, included participants who completed the intervention, or used another definition. No statistical analysis plan or interim-analysis information is reported in the registry record. These gaps prevent assessment of how multiplicity, missingness, and analysis-set choices may have affected the reported findings; numerical findings themselves are not reported.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent non-serious adverse event terms

The registry record lists serious adverse events for the Healthy Control and AE-PCOS groups. For each group, the number at risk for serious adverse events is 14 and the number affected is 0. The listed deaths are 0 in each group. For other adverse events, the number at risk is 14 and the number affected is 1 in each group. No top serious-event terms are listed.

These are registry counts, not estimates of comparative risk. The record does not give details about event type, timing, severity, relatedness, or how adverse events were collected. It also does not explain whether the listed at-risk figures correspond to all participants exposed to an intervention or another safety population. The absence of listed serious events should therefore be read narrowly as the recorded count, not as proof that no safety concerns occurred.

In general, safety counts are more informative when their definitions, observation periods, and analysis populations are clear. Here, those details are not reported in the registry record. The figures do not establish a difference between groups, and they do not support a broader conclusion about safety.

12. What the Result Does, and Does Not, Mean

This record documents a randomized early phase 1 study of baroreflex response to lower body negative pressure in the context of AE-PCOS and healthy controls. It specifies a physiological endpoint, the measurement approach, and three assessment conditions. It also lists GnRH antagonist and GnRH antagonist combined with MethylTESTOSTERone 5 MG as drug interventions.

The record does not report numerical results for the primary endpoint. Without means, variability, contrasts, confidence intervals, or tests, it is not possible to state whether the measured response changed, whether groups differed, or how precise an estimate might be. A measurement definition is not evidence of an observed effect. Likewise, the randomized label describes a design feature, not a result.

The available information does not establish how the intervention entries map to the two arm descriptions, which comparison was primary, or how repeated assessments were analyzed. The terminated status does not explain why the study stopped or whether the planned assessments were completed. These omissions make it especially important not to infer a treatment effect or a physiological pattern from the title, rationale, or design labels.

In general, a confidence interval communicates the range of values compatible with an estimate and its statistical uncertainty under an analysis model. A small or large estimate cannot be judged precisely without its uncertainty and context. Since the primary endpoint estimates and intervals are not reported in the registry record, neither the magnitude nor precision of a finding can be evaluated.

The record's content supports a description of what investigators intended to measure, not a conclusion about what the data demonstrated. No medical advice or treatment implication follows from the design alone. The listed secondary outcomes and adverse-event counts also do not supply the missing primary endpoint results or an overall conclusion about the study question.

13. Why This Trial Matters Statistically

This study illustrates an important distinction in clinical research reporting: a detailed endpoint definition is not the same as a reported result. The record identifies baroreflex response to LBNP, explains its physiological interpretation, and specifies assessment conditions. Yet without numerical estimates and uncertainty, readers cannot evaluate the size or precision of any observed response.

The design also demonstrates why a clearly defined contrast matters. The registry record identifies Healthy Control and AE-PCOS groups, randomized allocation, a parallel model, and drug interventions. It does not clarify how the interventions relate to the groups or which group-by-time comparison answers the primary question. Those details are needed to interpret an analysis, even when the measurement itself is described carefully.

Repeated assessment conditions create statistical questions about within-participant dependence, group comparisons, and multiplicity. In general, measurements from the same participant are not necessarily independent, and treating them as independent can misstate uncertainty. The record does not report how repeated measures were modeled or how multiple outcomes and comparisons were handled. These are not technical details detached from interpretation; they affect what an estimate means and how confidently it can be read.

Finally, termination and enrollment figures should not be treated as substitutes for participant-flow or analysis information. The record does not state why the study terminated or how many measurements contributed to a particular analysis. Careful statistical reading therefore separates what is documented—the design labels, endpoint definition, time points, and safety counts—from what is unreported: the outcome estimates, their uncertainty, and the analysis decisions needed to interpret them.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation for statistical interpretation is that numerical results for the primary endpoint are not reported in the registry record. Without outcome estimates, dispersion values, confidence intervals, or test results, no direction, magnitude, or precision can be assessed. The same limitation applies to the listed secondary outcomes, aldosterone and renal responses.

The endpoint is assessed at baseline, 7 days of GnRH, and 16 days of GnRH plus 5 days of testosterone, but a primary contrast is not specified. The record does not state how the Healthy Control and AE-PCOS groups relate to the listed drug interventions. It also does not report the model used for the continuous outcome, the treatment of repeated measurements, covariate adjustments, or how the analyses were selected.

Enrollment is listed as 28, but the number of analyzed observations at each assessment is not reported. Participant flow, completion, exclusions, missing-data reasons, and analysis populations are not described. The reason for termination is not reported in the registry record, so the implications of termination for data collection and analysis cannot be determined.

The record lists 10 outcome measures and 9 analyses but does not report prespecification, multiplicity handling, or an analysis plan. Randomization is recorded, but its procedure and allocation details are not reported; masking is recorded as none. These gaps constrain assessment of bias, precision, and the relationship between the design and the analysis. The safety counts are also limited by the absence of event definitions, timing, and attribution details.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome — NCT04327934.
• Registry record last updated 2024-02-02; status last verified 2024-01.
• Results first posted 2024-02-02.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT04327934 is titled “Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome.” The registry record describes an early phase 1, randomized, unmasked, parallel study sponsored by Yale University, with enrollment listed as 28 and status recorded as terminated. The start date is 2017-12-01, and the primary completion date is 2022-06-30.

The primary outcome is baroreflex response to LBNP, defined using forearm blood flow divided by mean arterial pressure as a linear function of lower body negative pressure. Assessments are listed at baseline, 7 days of GnRH, and 16 days of GnRH plus 5 days of testosterone. The record names Healthy Control and AE-PCOS groups and lists GnRH antagonist and GnRH antagonist + MethylTESTOSTERone 5 MG as interventions.

Aldosterone and renal responses are listed as secondary outcomes. Numerical primary and secondary outcome results, the reason for termination, the primary comparison, and analysis details are not reported in the registry record.